Key market opportunities include rising demand for adaptive investment strategies, increased use of predictive analytics in ...
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback